Clinical trial

IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA

NCT02451748

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2015-08-01

PhasePHASE4

Study timeline

Study start (actual)2015-08-01Date precision: month

Registry last updated2024-07-10

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Rheumatoid Arthritisunresolved

Interventions

Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg)DRUG

Certolizumab pegol (CDP870, tradename Cimzia)DRUG

HydroxychloroquineDRUG · verified · RxNorm: hydroxychloroquine

SulfasalazineDRUG · verified · RxNorm: sulfasalazine

MedrolDRUG · verified · RxNorm: Medrol

PrednisoneDRUG · verified · RxNorm: prednisone

TriamcinoloneDRUG · verified · RxNorm: triamcinolone

NaproxenDRUG · verified · RxNorm: naproxen

LeflunomideDRUG · verified · RxNorm: leflunomide

MethotrexateDRUG · verified · RxNorm: methotrexate

humiraDRUG · verified · RxNorm: Humira

Sponsors & collaborators

University of Illinois at Chicagolead sponsor

UCB Pharmacollaborator

Mapped research locations

ChicagoIllinois, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02451748 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.